Press Releases
Metabolons Vitamin D Deficiency Test Now Available for Patient Analysis Metabolon
Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today that it is now offering a tandem mass spectrometry (LC/MS/MS) test for detection of Vitamin D deficiency. The test is being run in Metabolon’s high-complexity CLIA...
Press Releases
National Labor Union Apologizes for False and Defamatory Mass Mailing SUTTER HEALTH
A large, national labor union will pay Sutter Health $6 million and has formally apologized for sending false and disparaging postcards to consumers in numerous communities served by Sutter-affiliated hospitals and birthing centers. The apology...
Press Releases
Diamyd Appoints Peter Zerhouni as President Diamyd Medical
Peter Zerhouni has been involved in all aspects of the Company since 2006 and he is since April 2011 Acting President and CEO of the Company. He assumes his position as President and CEO of Diamyd Medical AB on...
Press Releases
Merck Receives Approval to Market GARDASIL®, ZOLINZA® and CUBICIN® in Japan
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved three products - GARDASIL® , ZOLINZA® (vorinostat) and CUBICIN® (daptomycin for injection) – for...
Press Releases
CiToxLAB appoints Paul C. Barrow as director of scientific projects and client consulting
CiToxLAB, a leading CRO in the field of non-clinical research, announces today that Paul C. Barrow has joined the company after serving ten years as a director of toxicology at Ricerca Biosciences. Barrow has more than...
Press Releases
Alkermes Announces Positive Results from Clinical Study of ALKS 9070 For Treatment of Schizophrenia
Alkermes, Inc. (NASDAQ: ALKS) today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia. ALKS 9070, a proprietary Alkermes molecule for the treatment of...
Press Releases
Provence Technologies and NexGenix announce successful lead compound development
Provence Technologies, a service provider in fine organic chemistry, and NexGenix Pharmaceuticals, a discovery and development company focused on the "next generation" of targeted therapies for cancer and diseases of the nervous system, announce today a successful collaboration for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read